NuSirt Health

NuSirt Biopharma is a clinical-stage biopharmaceutical company focused on developing novel combination therapies for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The company's proprietary technology platform utilizes the amino acid leucine to synergistically enhance the activity of sirtuin 1 (SIRT1) and other metabolic pathways. By combining leucine with low doses of existing medications like metformin or sildenafil, NuSirt aims to improve therapeutic efficacy while reducing potential side effects. Their lead candidate, NS-0200, has been evaluated in Phase 2 clinical trials for the treatment of fatty liver disease, showing potential in reducing liver fat content. The company's approach leverages metabolic sensing pathways to address the growing global burden of chronic metabolic conditions.